TY - JOUR
T1 - Immunogenicity of Adalimumab in Patients with Non-Infectious- Uveitis
T2 - Systematic Review and Meta-Analysis
AU - Pachón-Suárez, Diana Isabel
AU - Zárate-Pinzón, Laura
AU - Cifuentes-González, Carlos
AU - Rojas-Carabali, William
AU - Mejía-Salgado, Germán
AU - Pineda, Juan Sebastián
AU - Peña-Pulgar, Luisa Fernanda
AU - de-la-Torre, Alejandra
N1 - Publisher Copyright:
© 2023 Taylor & Francis Group, LLC.
PY - 2023
Y1 - 2023
N2 - Objective: To review the prevalence, incidence, and risk factors for developing anti-drug antibodies (AAA) in patients with non-infectious uveitis (NIU) treated with Adalimumab (ADA). Methods: A systematic literature search was performed on PubMed, EMBASE, Virtual Health Library, Cochrane, and medRxiv. Meta-analysis was performed using random effects. Results: Nine out of 2,373 studies were included. The prevalence of AAA in NIU patients treated with ADA was 9% (95% CI: 2% to 37%, I2 = 95% with a P<0.01), it was significantly higher in real-life scenarios (observational studies) than in clinical trials. The pooled incidence at 12 months was 27% (CI 95% 16%-42% I2 = 0%). Several factors have been associated with AAA generation in NIU patients, including the non-use of concomitant immunosuppressants, presence of autoimmune systemic disease, female gender, etc. Conclusion: This study showed that AAA prevalence is higher in real-life scenarios compared to clinical trials. Further research is needed to elucidate the factors that trigger AAA generation in NIU patients.
AB - Objective: To review the prevalence, incidence, and risk factors for developing anti-drug antibodies (AAA) in patients with non-infectious uveitis (NIU) treated with Adalimumab (ADA). Methods: A systematic literature search was performed on PubMed, EMBASE, Virtual Health Library, Cochrane, and medRxiv. Meta-analysis was performed using random effects. Results: Nine out of 2,373 studies were included. The prevalence of AAA in NIU patients treated with ADA was 9% (95% CI: 2% to 37%, I2 = 95% with a P<0.01), it was significantly higher in real-life scenarios (observational studies) than in clinical trials. The pooled incidence at 12 months was 27% (CI 95% 16%-42% I2 = 0%). Several factors have been associated with AAA generation in NIU patients, including the non-use of concomitant immunosuppressants, presence of autoimmune systemic disease, female gender, etc. Conclusion: This study showed that AAA prevalence is higher in real-life scenarios compared to clinical trials. Further research is needed to elucidate the factors that trigger AAA generation in NIU patients.
UR - http://www.scopus.com/inward/record.url?scp=85173429078&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85173429078&partnerID=8YFLogxK
U2 - 10.1080/09273948.2023.2256850
DO - 10.1080/09273948.2023.2256850
M3 - Article
C2 - 37796609
AN - SCOPUS:85173429078
SN - 0927-3948
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
ER -